SLC7A2

Across TCGA pan-cancer cohorts, SLC7A2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC7A2 data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SLC7A2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC7A2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, BLCA, and DLBC are the cancer types where SLC7A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.178	0.813	<.001	27	view →
BLCA	OS	Median	All	0.141	0.687	.003	21	view →
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	18	view →
UCEC	DFS	Median	All	0.944	0.618	.016	8	view →
SARC	DFS	Median	All	0.179	0.612	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SLC7A2–LUAD (DFS)

Open the LUAD breakdown →